<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590342</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000247-27</org_study_id>
    <nct_id>NCT01590342</nct_id>
  </id_info>
  <brief_title>Diclofenac for Submassive PE</brief_title>
  <acronym>AINEP-1</acronym>
  <official_title>Efficacy of Diclofenac for Patients With Acute Submassive Pulmonary Embolism: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the clinical benefits of diclofenac (added to
      standard anticoagulant therapy) over placebo in normotensive patients with acute symptomatic
      pulmonary embolism and right ventricular dysfunction.

      The secondary objective is to assess the safety after administration of diclofenac in
      normotensive patients with acute symptomatic pulmonary embolism and right ventricular
      dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular dysfunction assessed by transthoracic echocardiography</measure>
    <time_frame>36-48 hours after administration of the first dose of diclofenac/placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular dysfunction assessed by transthoracic echocardiography</measure>
    <time_frame>Seven days after administration of diclofenac/placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Diclofenac 75 mg, two doses</description>
    <arm_group_label>Diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, two doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute symptomatic PE confirmed by multidetector CT angiography, a high-probability V/Q
             scan, or by the presence of deep vein thrombosis confirmed by lower limb ultrasound
             testing in patients with nonconclusive V/Q scan;

          2. first symptoms occurring ten days or less before randomization;

          3. haemodynamic stability (systolic blood pressure &gt; 100 mm Hg, no need of inotropic
             support, pulmonary resuscitation, intubation or thrombolytic treatment);

          4. right ventricular dysfunction assessed by transthoracic echocardiography within the
             first 12 hours after diagnosis of PE;

          5. signed informed consent.

        Exclusion Criteria:

          1. Previous diagnosis of chronic thromboembolic pulmonary hypertension;

          2. active bleeding, or clinically relevant bleeding in the previous month before
             diagnosis of PE;

          3. peptic ulcer;

          4. major surgery, or severe trauma in the previous month before diagnosis of PE;

          5. indication for chronic anticoagulation;

          6. pregnancy or breast feeding;

          7. renal insufficiency (serum creatinine &gt; 2 mg/dL) or severe hepatic impairment;

          8. hypersensitivity to diclofenac, sodium metabisulfite, or acetylsalicylic acid;

          9. bronchial asthma;

         10. severe congestive heart failure;

         11. inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jimenez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ramon y Cajal Hospital, IRYCIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital, IRYCIS</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Spain</investigator_affiliation>
    <investigator_full_name>David Jimenez</investigator_full_name>
    <investigator_title>Clinical researcher</investigator_title>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Right ventricular dysfunction</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

